Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.
Patel DA, Gopalakrishnan R, Engelhardt BG, McArthur E, Sengsayadeth S, Culos KA, Byrne M, Goodman S, Savani BN, Chinratanalab W, Jagasia M, Mosse CA, Cornell RF, Kassim AA.
Patel DA, et al. Among authors: mosse ca.
Bone Marrow Transplant. 2020 Jun;55(6):1137-1146. doi: 10.1038/s41409-020-0791-y. Epub 2020 Jan 28.
Bone Marrow Transplant. 2020.
PMID: 31992845
Free PMC article.